Finance

Lists
Why is KNSA down 8,09%?
Dive Deeper
KNSA:NASDAQ
Kiniksa Pharmaceuticals Internatinl, PLC
88,34 US$
-8,09%
(-7,78) 1D
89,50 US$
+1,31% (+1,16)
After hours
Closed: 5 ნოე, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KNSA...
Open
95,49 US$
High
96,99 US$
Low
87,30 US$
Mkt. cap
6,94 მლრდ.
Avg. vol.
813,28 ათ.
Volume
4,00
P/E ratio
67,43
52-wk high
98,48 US$
52-wk low
37,02 US$
EPS
1,31 US$
Beta
0,07
Shares outstanding
48,84 მლნ.
No. of employees
366
Open
95,49 US$
High
96,99 US$
Low
87,30 US$
Mkt. cap
6,94 მლრდ.
Avg. vol.
813,28 ათ.
Volume
4,00
P/E ratio
67,43
52-wk high
98,48 US$
52-wk low
37,02 US$
EPS
1,31 US$
Beta
0,07
Shares outstanding
48,84 მლნ.
No. of employees
366
News stories
From web sources and news partners
About Kiniksa Pharmaceuticals Internatinl, PLC
CEO-
Employees366
Founded2015
Headquartersლონდონი, ინგლისი, გაერთიანებული სამეფო
SectorHealth Care
Industry-
Analyst ratings
Based on 5 analysts giving stock ratings to KNSA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KNSA in the last 3 months.
Highest
Current 88,34 US$
122,00 US$ (+38,10%)
Average
106,20 US$ (+20,22%)
Lowest
98,00 US$ (+10,94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Reiterated
122,00 US$
+38,1%
10/30/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
98,00 US$
+10,9%
10/28/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
110,00 US$
+24,5%
10/28/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
101,00 US$
+14,3%
10/27/2026
Geoff Meacham
Citi
Buy
Maintained
100,00 US$
+13,2%
10/15/2026
David Nierengarten
Wedbush
Buy
Reiterated
99,00 US$
+12,1%
07/28/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
87,00 US$
-1,5%
07/29/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
95,00 US$
+7,5%
07/28/2026
Roger Song
Jefferies
Buy
Maintained
71,00 US$
-19,6%
04/28/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
53,00 US$
-40%
04/14/2026
Last report
27 ოქტ. 2026
Fiscal period
Q3 2026
0,56 US$ / 0,31 US$
+79,20%beat
Revenue / Est. (USD)
285,97 მლნ. / 260,61 მლნ.
+9,73%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
202,13 მლნ.
214,27 მლნ.
243,60 მლნ.
285,97 მლნ.
Cost of goods sold
90,98 მლნ.
96,37 მლნ.
111,64 მლნ.
133,59 მლნ.
Cost of revenue
90,98 მლნ.
96,37 მლნ.
111,64 მლნ.
133,59 მლნ.
Research and development expenses
34,61 მლნ.
27,48 მლნ.
40,90 მლნ.
32,79 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
56,78 მლნ.
61,15 მლნ.
63,87 მლნ.
65,36 მლნ.
Operating expense
91,38 მლნ.
88,63 მლნ.
104,76 მლნ.
98,15 მლნ.
Total operating expenses
182,36 მლნ.
185,00 მლნ.
216,41 მლნ.
231,73 მლნ.
Operating income
19,77 მლნ.
29,27 მლნ.
27,19 მლნ.
54,24 მლნ.
Other non operating income
3,50 მლნ.
3,41 მლნ.
3,95 მლნ.
-169,00 ათ.
EBT including unusual items
23,27 მლნ.
32,68 მლნ.
31,14 მლნ.
59,06 მლნ.
EBT excluding unusual items
23,27 მლნ.
32,68 მლნ.
31,14 მლნ.
59,06 მლნ.
Income tax expense
9,07 მლნ.
10,09 მლნ.
5,71 მლნ.
11,71 მლნ.
Effective tax rate
38,98%
30,87%
18,34%
19,83%
Other operating expenses
-
-
-
-
Net income
14,20 მლნ.
22,59 მლნ.
25,43 მლნ.
47,34 მლნ.
Net profit margin
7,02%
10,54%
10,44%
16,56%
Earnings per share
0,17
0,27
0,30
0,56
Interest and investment income
-
-
-
4,99 მლნ.
Interest expense
-
-
-
-
Net interest expenses
-
-
-
4,99 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
20,24 მლნ.
29,74 მლნ.
27,67 მლნ.
54,73 მლნ.
Gain or loss from assets sale
-53,00 ათ.
-54,00 ათ.
22,00 ათ.
8,00 ათ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები